Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States

Edward Vincent Loftus, Jr, Xiaoyun Pan, Pete Zurawski, Parvez Mulani, Jingdong Chao

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background and aims: To determine the real-world dosage pattern of adalimumab and predictors for weekly dosing in Crohn's disease (CD). Methods: Patients with CD receiving adalimumab maintenance therapy (≥ 3 dispensing events within 1. year) were identified from a large specialty pharmacy database in the United States (March 2007-July 2008). Weekly dosing rates (≥ 2 consecutive weekly doses after the first dispensing event) for a 12-month period were estimated with Kaplan-Meier methods. Predictors for weekly dosing were identified using Cox proportional-hazards regression. Results: The overall adalimumab weekly dosing rate was 11.3% (151 of 1335 patients). The 12-month cumulative risk of weekly dosing was 15.5%. Patients who received a 160-/80-mg induction regimen had half the risk for weekly dosing compared with other induction regimens (hazard ratio, 0.48; 95% confidence intervals 0.33-0.7; p< 0.0001). Weekly dosing rates were significantly lower in the West and South vs. the Northeast. Conclusions: The adalimumab weekly dosing rate in a real-world, managed-care setting is less than that in clinical trials and academic centres. Geographic region and not starting on 160-/80-mg induction therapy were significantly associated with weekly adalimumab use for patients with CD.

Original languageEnglish (US)
Pages (from-to)550-544
Number of pages7
JournalJournal of Crohn's and Colitis
Volume5
Issue number6
DOIs
StatePublished - Dec 2011

Fingerprint

Crohn Disease
Managed Care Programs
Adalimumab
Clinical Trials
Databases
Confidence Intervals
Therapeutics

Keywords

  • Adalimumab
  • Crohn's disease
  • Pharmacy claims data
  • Predictors
  • Weekly dosing

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Adalimumab real-world dosage pattern and predictors of weekly dosing : Patients with Crohn's disease in the United States. / Loftus, Jr, Edward Vincent; Pan, Xiaoyun; Zurawski, Pete; Mulani, Parvez; Chao, Jingdong.

In: Journal of Crohn's and Colitis, Vol. 5, No. 6, 12.2011, p. 550-544.

Research output: Contribution to journalArticle

@article{577b8de618a3420ab9f2cb3b0b6d831c,
title = "Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States",
abstract = "Background and aims: To determine the real-world dosage pattern of adalimumab and predictors for weekly dosing in Crohn's disease (CD). Methods: Patients with CD receiving adalimumab maintenance therapy (≥ 3 dispensing events within 1. year) were identified from a large specialty pharmacy database in the United States (March 2007-July 2008). Weekly dosing rates (≥ 2 consecutive weekly doses after the first dispensing event) for a 12-month period were estimated with Kaplan-Meier methods. Predictors for weekly dosing were identified using Cox proportional-hazards regression. Results: The overall adalimumab weekly dosing rate was 11.3{\%} (151 of 1335 patients). The 12-month cumulative risk of weekly dosing was 15.5{\%}. Patients who received a 160-/80-mg induction regimen had half the risk for weekly dosing compared with other induction regimens (hazard ratio, 0.48; 95{\%} confidence intervals 0.33-0.7; p< 0.0001). Weekly dosing rates were significantly lower in the West and South vs. the Northeast. Conclusions: The adalimumab weekly dosing rate in a real-world, managed-care setting is less than that in clinical trials and academic centres. Geographic region and not starting on 160-/80-mg induction therapy were significantly associated with weekly adalimumab use for patients with CD.",
keywords = "Adalimumab, Crohn's disease, Pharmacy claims data, Predictors, Weekly dosing",
author = "{Loftus, Jr}, {Edward Vincent} and Xiaoyun Pan and Pete Zurawski and Parvez Mulani and Jingdong Chao",
year = "2011",
month = "12",
doi = "10.1016/j.crohns.2011.05.005",
language = "English (US)",
volume = "5",
pages = "550--544",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Adalimumab real-world dosage pattern and predictors of weekly dosing

T2 - Patients with Crohn's disease in the United States

AU - Loftus, Jr, Edward Vincent

AU - Pan, Xiaoyun

AU - Zurawski, Pete

AU - Mulani, Parvez

AU - Chao, Jingdong

PY - 2011/12

Y1 - 2011/12

N2 - Background and aims: To determine the real-world dosage pattern of adalimumab and predictors for weekly dosing in Crohn's disease (CD). Methods: Patients with CD receiving adalimumab maintenance therapy (≥ 3 dispensing events within 1. year) were identified from a large specialty pharmacy database in the United States (March 2007-July 2008). Weekly dosing rates (≥ 2 consecutive weekly doses after the first dispensing event) for a 12-month period were estimated with Kaplan-Meier methods. Predictors for weekly dosing were identified using Cox proportional-hazards regression. Results: The overall adalimumab weekly dosing rate was 11.3% (151 of 1335 patients). The 12-month cumulative risk of weekly dosing was 15.5%. Patients who received a 160-/80-mg induction regimen had half the risk for weekly dosing compared with other induction regimens (hazard ratio, 0.48; 95% confidence intervals 0.33-0.7; p< 0.0001). Weekly dosing rates were significantly lower in the West and South vs. the Northeast. Conclusions: The adalimumab weekly dosing rate in a real-world, managed-care setting is less than that in clinical trials and academic centres. Geographic region and not starting on 160-/80-mg induction therapy were significantly associated with weekly adalimumab use for patients with CD.

AB - Background and aims: To determine the real-world dosage pattern of adalimumab and predictors for weekly dosing in Crohn's disease (CD). Methods: Patients with CD receiving adalimumab maintenance therapy (≥ 3 dispensing events within 1. year) were identified from a large specialty pharmacy database in the United States (March 2007-July 2008). Weekly dosing rates (≥ 2 consecutive weekly doses after the first dispensing event) for a 12-month period were estimated with Kaplan-Meier methods. Predictors for weekly dosing were identified using Cox proportional-hazards regression. Results: The overall adalimumab weekly dosing rate was 11.3% (151 of 1335 patients). The 12-month cumulative risk of weekly dosing was 15.5%. Patients who received a 160-/80-mg induction regimen had half the risk for weekly dosing compared with other induction regimens (hazard ratio, 0.48; 95% confidence intervals 0.33-0.7; p< 0.0001). Weekly dosing rates were significantly lower in the West and South vs. the Northeast. Conclusions: The adalimumab weekly dosing rate in a real-world, managed-care setting is less than that in clinical trials and academic centres. Geographic region and not starting on 160-/80-mg induction therapy were significantly associated with weekly adalimumab use for patients with CD.

KW - Adalimumab

KW - Crohn's disease

KW - Pharmacy claims data

KW - Predictors

KW - Weekly dosing

UR - http://www.scopus.com/inward/record.url?scp=80051806028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051806028&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2011.05.005

DO - 10.1016/j.crohns.2011.05.005

M3 - Article

C2 - 22115373

AN - SCOPUS:80051806028

VL - 5

SP - 550

EP - 544

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 6

ER -